Antiva Biosciences nabs $16 mln Series B
Biopharmaceutical company Antiva Biosciences Inc has secured $16 million in Series B funding. Canaan Partners and Sofinnova Ventures led the round. In conjunction with the funding, Wende Hutton, a general partner at Canaan Partner and David Kabakoff, an executive partner at Sofinnova Ventures, have been added to Antiva's board of directors. Also, the company has named Gail Maderis as president and CEO and Steven P. James as executive chairman of the board.
6 August 2015•3 mins read
